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Common variants in 94 loci have been associated with breast cancer including 15 loci with
genome-wide signiﬁcant associations (Po5 108) with oestrogen receptor (ER)-negative
breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new
ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association
studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with
7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped
on the iCOGS array. We identify four previously unidentiﬁed loci including two loci at 13q22
near KLF5, a 2p23.2 locus nearWDR43 and a 2q33 locus near PPIL3 that display genome-wide
signiﬁcant associations with ER-negative breast cancer. In addition, 19 known breast cancer
risk loci have genome-wide signiﬁcant associations and 40 had moderate associations
(Po0.05) with ER-negative disease. Using functional and eQTL studies we implicate
TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All
ER-negative loci combined account for B11% of familial relative risk for ER-negative disease
and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.
Correspondence and requests for materials should be addressed to F.C. (email: couch.fergus@mayo.edu).
#A full list of authors and their afﬁliations appears at the end of the paper.
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B
reast cancer is a heterogeneous disease that can be
separated into clinical subtypes based on tumour histolo-
gical markers, such as the oestrogen receptor (ER).
ER-negative disease accounts for 20–30% of all breast cancers,
is more common in women diagnosed at young age and in
women of African ancestry1, and is associated with worse short-
term outcome than ER-positive disease. ER-negative and ER-
positive breast cancer also exhibit different patterns of genetic
susceptibility2. Currently, 94 loci containing common breast
cancer risk-associated variants have been associated with breast
cancer through genome-wide association studies (GWAS), and
large replication studies3–18. However, only 14 loci have shown
genome-wide signiﬁcant associations (Po5 10 8) with
ER-negative disease3,17–20. While this partly reﬂects the smaller
sample size for ER-negative disease, the majority of the known
breast cancer loci show differences in relative risk by subtype. In
particular, 6 of the 14 loci associated with ER-negative disease at
genome-wide signiﬁcance show no evidence of association with
ER-positive disease20. The alleles associated with ER-negative
breast cancer3,17 at these loci have also been associated with
breast cancer risk in BRCA1 mutation carriers21,22, consistent
with the ﬁnding that the majority of breast tumours arising in
BRCA1 mutation carriers show low/absent expression of ER23–25.
These observations suggest that a meta-analysis of results from
ER-negative breast cancer and BRCA1 breast cancer association
studies could identify additional ER-negative susceptibility loci
that were not found previously because of limited sample size.
In this study, we carried out a meta-analysis of breast cancer
GWAS studies and found four new loci associated with
developing ER-negative breast cancer.
Results
Associations with ER-negative breast cancer. Genotype data for
this meta-analysis were obtained from three sources: (1) 11 breast
cancer GWAS included 5,139 ER-negative breast cancer cases and
14,352 controls (Supplementary Table 1); (2) The Breast Cancer
Association Consortium (BCAC) included 7,333 ER-negative
breast cancer cases and 42,468 study-matched controls genotyped
on the iCOGS (Collaborative Oncological Gene-environment
Study) custom array3; (3) The Consortium of Investigators of
Modiﬁers of BRCA1/2 (CIMBA)26 included 15,252 BRCA1
mutation carriers (7,797 with breast cancer and 7,455 unaffected)
genotyped on the iCOGS array (Supplementary Tables 2–4).
Imputation was performed using the 1000 Genomes project as a
reference20,27, and a meta-analysis was performed based on
10,909,381 common single-nucleotide polymorphisms (SNPs)
that passed quality control (Supplementary Table 1).
We ﬁrst considered SNPs in 94 regions in which genome-wide
signiﬁcant associations for breast cancer had been identiﬁed
(Methods)20. In 55 of these, the SNP most signiﬁcantly associated
with overall breast cancer risk was signiﬁcantly associated
(Po0.05) with ER-negative breast cancer in the meta-analysis.
Four more were associated with ER-negative breast cancer in the
general population (Po0.05) but not in the meta-analysis, and 15
displayed genome-wide signiﬁcant (Po5 10 8) associations
with ER-negative breast cancer (Supplementary Table 5). In
addition, new SNPs in three loci (rs10864459 from 1p36.2 PEX14,
rs11903787 from INHBB and rs4980383 from 11p15.5 LSP1)
were found to have genome-wide signiﬁcant associations with
ER-negative disease (Table 1, Fig. 1, Supplementary Table 5).
Likewise, SNPs in the TCF7L2 locus previously associated with
BRCA1 breast cancer22 and ER-positive breast cancer3,20 showed
genome-wide signiﬁcant associations with ER-negative breast
cancer (Table 1). Interestingly multiple independent signals in
several loci were associated with ER-negative breast cancer. In
particular, three independent regions in the TERT locus28, two
regions in PTHLH, and two regions in ESR1 displayed genome-
wide signiﬁcant associations with ER-negative breast cancer
(Table 1). Furthermore, while previous studies established
genome-wide signiﬁcant associations with ER-negative disease
for rs11075995 in one 16q12.2 FTO locus17, rs17817449
(r2¼ 0.035) from a second FTO locus located 40 kb proximal to
the rs11075995 tagged locus17 also displayed near-genome-wide
signiﬁcance (P¼ 5.26 10 8) with ER-negative breast cancer in
the meta-analysis (Table 1). In addition to the breast cancer loci
established in studies of European women, three additional breast
cancer risk loci were recently identiﬁed in GWAS of Asian
women. To generalize the results to other populations,
associations between the three SNPs and breast cancer in the
European, African American and Asian populations in the
iCOGS study were evaluated. SNP rs2290203 showed only weak
evidence of association (P¼ 0.02), and rs4951011 and rs10474352
SNPs showed no evidence of association with ER-negative breast
cancer in the white European meta-analysis (Supplementary
Table 6).
Among the 94 known risk loci from white European and three
from Asian populations, only 24 contained SNPs with some
evidence of association (Po0.05) with breast cancer risk among
BRCA1 mutation carriers alone. These included 21 loci based on
known index SNPs (Supplementary Table 5) along with new
SNPs from the meta-analysis in the PEX14 (rs10864459), INHBB
(rs11903787) and PTHLH (rs7297051) loci (Table 1). Only the
ESR1 (rs2046210), TERT (rs2242652) and two 19p13.1 (rs8170;
rs56069439) loci had genome-wide signiﬁcant associations with
breast cancer risk for BRCA1 mutation carriers alone (Table 1,
Supplementary Table 5). However, 15 of the 19 risk loci that
reached genome-wide signiﬁcance for ER-negative disease in the
meta-analysis showed some evidence of association (Po0.05)
with breast cancer risk for BRCA1 mutation carriers using a
retrospective likelihood analysis12. These SNPs had hazard ratio
(HR) estimates in BRCA1 carriers that were similar to the odds
ratio (OR) estimates for ER-negative breast cancer (Table 1). In
contrast, four SNPs in the LGR6, 2p24.1, ZNF365 and FTO loci
had HR estimates ranging from 0.97 to 1.01 and were not
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Figure 1 | Manhattan plot of ER-negative breast cancer meta-analysis.
The Manhattan plot displays the strength of genetic association ( log10 P)
versus chromosomal position (Mb), where each dot presents a genotyped
or imputed (black circle) SNP. The black horizontal line represents the
threshold for genome-wide signiﬁcance (P¼ 5 108).
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signiﬁcantly associated (P40.05) with breast cancer risk for
BRCA1 mutation carriers. No signiﬁcant interactions between the
known risk SNPs were observed when pairwise interactions were
evaluated separately in the general population (BCAC-iCOGS) or
in BRCA1 carriers after adjusting for multiple testing.
Genome-wide associations with ER-negative breast cancer.
Novel genome-wide signiﬁcant associations (Po5 10 8) were
detected with imputed and genotyped SNPs on chromosomes
2p23.2 and 13q22 (Table 2, Fig. 2, Supplementary Fig. 1). At 2p23.2,
79 SNPs exhibited genome-wide signiﬁcant associations with ER-
negative breast cancer (Fig. 2, Supplementary Fig. 2, Supplementary
Table 7). The most signiﬁcant genotyped and imputed SNPs at
these two loci were rs4577244 (P¼ 1.0 10 8) and rs67073037
(P¼ 4.76 10 9), respectively (Table 2). To investigate the pre-
sence of independent signals at the 2p23.2 locus, conditional ana-
lyses were conducted adjusting for the lead SNP. However, no
signiﬁcant (Po0.05) associations were observed at 2p23.2 after
adjusting for rs67073037. In the 13q22 locus, rs6562760 was the
most strongly associated (P¼ 5.0 10 10) SNP among 12 gen-
ome-wide signiﬁcant SNPs (Table 2, Supplementary Table 8,
Fig. 2, Supplementary Fig. 1). Conditional analysis adjusting for
rs6562760 yielded several SNPs with residual associations for
ER-negative breast cancer, with rs17181761 (r2¼ 0.51) as the most
signiﬁcantly associated (P¼ 6.0 10 6) (Supplementary Table 9).
No associations at Po10 4 remained after conditioning on both
rs6562760 and rs17181761. Thus, 13q22 appears to contain two
independent ER-negative risk loci.
When considering only the data from the general population
using the BCAC-iCOGS studies, no association between
rs67073037 at 2p23.2 and ER-positive breast cancer was observed
(Supplementary Table 10). Consistent with this observation, a
signiﬁcant difference (Pdiff¼ 4.45 10 6) in the per-allele ORs
for ER-positive and ER-negative breast cancer was detected.
In contrast, rs17181761 at 13q22 was weakly associated with
ER-positive breast cancer (OR¼ 1.03; P¼ 0.030), but more
strongly associated with ER-negative breast cancer (OR¼ 1.08;
Pdiff¼ 5.82 10 3; Supplementary Table 10). Likewise,
rs6562760 at 13q22 was more strongly associated with ER-
negative than ER-positive breast cancer (ER-positive OR¼ 0.98
versus ER-negative OR¼ 0.92; Pdiff¼ 0.028) (Supplementary
Table 10). Among ER-negative cases, no signiﬁcant differences
in the ORs for triple negative (ER-negative, progesterone receptor
negative, HER2 negative) and non-triple-negative cases was
observed (rs67073037, Pdiff¼ 0.26; rs6562760, Pdiff¼ 0.36;
rs17181761, Pdiff¼ 0.69). Q-tests were used to assess hetero-
geneity. These results suggest that the three risk loci are largely
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Figure 2 | Novel ER-negative breast cancer loci. The chromosomal position and strength of genetic association ( log10 P) is shown for all SNPs
(Po1 106) in BCAC/iCOGS data in the four novel risk loci. (a). 2p23 locus. The most signiﬁcant SNP (rs67073037) is shown as a diamond. (b). 13q22
loci. The most signiﬁcant SNP (rs6562760) is shown as a diamond. The second locus is shown in black. (c). 2q33 locus. The most signiﬁcant SNPs
(rs188686860; rs115635831) are shown as diamonds.
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speciﬁc to ER-negative but not triple-negative breast cancer, in
contrast to loci in the MDM4, LGR6, 19p13.1 and TERT
regions3,17. To also investigate the impact of bilateral disease on
the associations with ER-negative breast cancer in the general
population, analyses were performed separately for BBCS alone,
which oversampled for bilateral cases, and after exclusion of
BBCS. The risk estimates for each SNP (both in iCOGS and in the
meta-analysis), after excluding BBCS, did not differ from the
main results (Supplementary Table 11), and do not appear to be
substantially inﬂuenced by bilateral cases.
Using the retrospective likelihood approach, index SNPs in the
three 2p23.2 and 13q22 loci were all associated with BRCA1 breast
cancer (rs67073037, P¼ 4.58 10 4; rs6562760, P¼ 2.85 10 6;
rs17181761, P¼ 9.29 10 3; Table 2). There were no signiﬁcant
differences in the associations with ER-positive and ER-negative
disease among BRCA1 carriers (Supplementary Table 12). A
competing risks analysis in BRCA1 mutation carriers that accounted
for simultaneous associations with breast and ovarian cancer risks
found similar HR estimates for breast cancer and no evidence of
association with ovarian cancer risk (Supplementary Table 13). None
of the SNPs were associated with overall breast cancer risk for BRCA2
mutation carriers (Supplementary Table 10). There was also no
signiﬁcant evidence of heterogeneity (Po0.05) between the effect
estimates for BRCA1mutation carriers and ER-negative breast cancer
in the general population (BCAC-iCOGS; Intraclass Correlation)27.
Finally, no signiﬁcant interactions between the three index SNPs and
any of the 94 previously known loci were observed in BRCA1 carriers
or in the general population after adjusting for multiple testing
(Supplementary Table 14).
Association with ER-negative breast cancer in the 2q33 locus.
Analysis of genotyped and imputed SNPs around known risk
loci also detected near-genome-wide signiﬁcant associations with
ER-negative breast cancer in a region on 2q33 containing
several genes including PPIL3 and the known CASP8 risk locus
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Figure 3 | The chromatin landscape of locus 2p23.2. (a) The SNP rs4407214 is included in a genomic tile overlapping chromatin features indicative of
promoters and enhancers, shaded red. (b,c). Luciferase assays showing activity in the tile containing SNP rs4407214 (highlighted in pink in a.) in MCF10A
and CAL51, red box plots indicate signiﬁcantly different from the control tile (Po0.0001). Brown box plot indicates signiﬁcant difference from the reference
allele (P¼ 0.0059). (d) Electrophoretic mobility shift assay (EMSA) showing the formation of allele-speciﬁc complexes for rs4407214. M, major allele; m,
minor allele. Lines 1, 2, 7, 8—no nuclear extract. Lines 3, 4, 5, 6—10 mg of MCF10A nuclear extract. Lines 9, 10, 11, 12—10mg of CAL51 nuclear extract. Shift
detected by comparison to bands (arrows #1 and #2).
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(Table 2). rs115635831 (P¼ 1.26 10 7) and rs188686860
(P¼ 8.34 10 8; r2¼ 1.0), were the genotyped and imputed
SNPs, respectively, most signiﬁcantly associated with ER-negative
breast cancer in this region. These SNPs, along with the most
proximal rs74943274 SNP (r2¼ 0.97 with rs115635831), are
located in CLK1 (Cdc-like kinase-1) and PPIL3 (Peptidylproplyl
isomerase-Like 3) and are 350 kb upstream of CASP8 (Table 2,
Fig. 2). All 157 SNPs with highly signiﬁcant associations
(Po1 10 6) in this region, were in high linkage disequilibrium
with rs188686860 and rs115635831 (r240.90), and were located
proximal (Hg19: 201,717,014-201,995,860) to the CASP8 gene
(Supplementary Table 15). Fine mapping of the CASP8 locus has
recently identiﬁed four independent signals associated with
overall breast cancer risk29. The index SNPs for these
independent signals range across a 350-kb region from
202,036,478 to 202,379,828. To determine whether these
CASP8-associated signals accounted for the ER-negative
associations in the meta-analysis, conditional analyses were
conducted using the BCAC-iCOGS data. After accounting for
the four CASP8 signals, rs74943274 retained evidence of an
association with overall breast cancer (P¼ 1.44 10 3) and a
strong association with ER-negative breast cancer
(P¼ 1.34 10 5; Supplementary Table 16; Supplementary
Fig. 2), suggesting that rs74943274 and rs115635831 represents
a novel locus associated with ER-negative breast cancer.
Further consideration of the BCAC-iCOGS data found no
association for rs115635831 at 2q33 with ER-positive breast cancer
(P¼ 0.23) but identiﬁed a signiﬁcant difference (Pdiff¼ 2.9 10 4)
in the per-allele ORs for ER-positive and ER-negative breast cancer
(Q-test, Supplementary Table 10). No inﬂuence of bilateral disease
was observed in sensitivity analyses (Supplementary Table 11).
However, the index SNPs in the 2q33 locus were signiﬁcantly
associated with BRCA1 breast cancer (rs115635831, P¼ 0.018;
rs188686860, P¼ 0.012; Table 2). While there were no signiﬁcant
differences in the associations with ER-positive and ER-negative
disease among BRCA1 carriers (PHet¼ 0.12), the associations were
stronger for ER-negative (rs115635831 HR¼ 1.32, P¼ 3 10 3)
than ER-positive breast cancer (rs115635831 overall HR¼ 1.21,
P¼ 0.018) using the retrospective likelihood model (Supplementary
Table 12). In addition, the associations for BRCA1 mutation carriers
were of similar magnitude as the OR estimates for ER-negative
breast cancer in BCAC-iCOGS27 (Supplementary Table 15). There
was also no evidence of intraclass heterogeneity (Po0.05) between
the effect estimates for BRCA1 mutation carriers and ER-negative
breast cancer in the general population (BCAC-iCOGS)27. A
competing risks analysis for BRCA1 mutation carriers found little
inﬂuence of ovarian cancer on risks of breast cancer (rs115635831
HR¼ 1.23, P¼ 0.016), and no evidence of association with ovarian
cancer risk using the retrospective likelihood model (Supplementary
Table 13). No association with overall breast cancer risk among
BRCA2 mutation carriers (Supplementary Table 10) was evident.
Interestingly, rs114962751 at 2q33 and rs150750171 at 6p had the
most signiﬁcant interaction (P¼ 3.9 10 4) among all known
breast cancer risk SNPs in the iCOGS data, although the interaction
was non-signiﬁcant after adjusting for multiple testing
(Supplementary Table 14). Altogether these results suggest the
presence of a novel locus associated with ER-negative breast cancer
that is located in the CLK1/PPIL3 region proximal to CASP8.
Expression quantitative trait locus (eQTL) analysis. To identify
the genes in the novel loci inﬂuenced by the observed associations
with ER-negative breast cancer, expression quantitative trait locus
(eQTL) analyses were performed using gene expression data from
breast tumour tissue and normal breast tissue and 1000 Genomes
Project imputed SNPs in 1Mb regions around the novel loci. In
the 2p23.2 locus, the strongest cis eQTL associations for 735
TCGA breast tumours (BC765) involved TRMT61B expression
(Supplementary Table 17). Most of the genome-wide signiﬁcant
ER-negative breast cancer risk SNPs in the locus displayed
associations with TRMT61B expression, including the imputed
SNPs (rs67073037, P¼ 1.47 10 5; Supplementary Fig. 3;
rs6734079, P¼ 1.85 10 5) and the genotyped SNP (rs4577254,
P¼ 5.61 10 5) most signiﬁcantly associated with risk
(Supplementary Table 18). Similarly, in a Norwegian normal
breast cohort of 116 normal breast tissues (NB116), the strongest
cis eQTLs associations involved TRMT61B expression and the
risk SNPs in the locus yielded signiﬁcant associations with
TRMT61B expression (Supplementary Table 17). While the peak
eQTL SNPs (rs6419696, P¼ 1.21 10 17) were not among the
SNPs showing the greatest association with risk (rs6419696,
P¼ 2.6 10 3), conditional analyses showed that the rs6419696
Table 1 | Common genetic variants from known breast cancer susceptibility loci displaying most signiﬁcant genome-wide
associations with ER-negative breast cancer risk.
Location Position Nearest
gene
SNP Alleles iCOGS/GWAS ER-negative BRCA1 carriers Meta-analysis
EAF OR (95% CI) P EAF HR (95% CI) P P*
Variants in known loci most signiﬁcantly associated with overall breast cancer
w1p36.2 10563609 PEX14 rs10864459 G/A 0.32 0.90 (0.87–0.93) 2.13 10 9 0.31 0.95 (0.91–0.99) 0.01 4.60 10 10
w1q32.1 202179042 LGR6 rs17489300 A/C 0.4 0.90 (0.87–0.93) 9.37 10 10 0.39 0.97 (0.93–1.01) 0.19 1.98 10 8
1q32.1 204518842 MDM4 rs4245739 A/C 0.26 1.13 (1.11–1.19) 5.53 10 15 0.28 1.09 (1.05–1.14) 6.83 10 5 7.71 10 18
2p24.1 19184284 2p24.1 rs12710696 C/T 0.36 1.10 (1.06–1.13) 1.70 10 8 0.39 1.01 (0.97–1.05) 0.56 1.90 10 6
w2q14.2 121088182 INHBB rs11903787 G/A 0.25 0.90 (0.86–0.94) 8.57 10 7 0.26 0.91 (0.87–0.96) 2.0 104 7.24 10 10
w5p15.3 1280028 TERT rs2242652 A/G 0.20 1.18 (1.13–1.23) 2.73 10 14 0.22 1.22 (1.16–1.28) 2.53 10 15 7.58 10 28
5p15.3 1282319 TERT rs7726159 A/C 0.34 1.09 (1.05–1.13) 2.19 10 6 0.35 1.07 (1.02–1.11) 1.79 10 3 3.31 10 8
5p15.3 1297488 TERT rs2736108 T/C 0.29 0.89 (0.86–0.93) 1.41 10 8 0.29 0.89 (0.86–0.93) 4.05 10 7 3.05 10 14
6q25.1 151918856 ESR1 rs12662670 T/G 0.08 1.20 (1.18–1.32) 8.90 10 15 0.09 1.19 (1.11–1.27) 9.67 10 7 1.32 10 19
w6q25.1 151946152 ESR1 rs11155804 A/T 0.34 1.16 (1.12–1.19) 8.18 10 18 0.36 1.15 (1.11–1.20) 0.02 3.75 10 28
10q21.2 64278682 ZNF365 rs10995190 G/A 0.16 0.89 (0.85–0.93) 3.75 108 0.16 0.99 (0.94–1.04) 0.66 8.23 10 6
w10q25.2 114782803 TCF7L2 rs6585202 T/C 0.46 1.06 (1.04–1.10) 3.35 10 5 0.47 1.10 (1.05–1.14) 6.08 10 6 1.32 10 9
w11p15.5 1902097 LSP1 rs4980383 C/T 0.44 1.08 (1.05–1.12) 3.02 10 6 0.45 1.07 (1.03–1.11) 7.73 104 9.41 10 9
w12p11.2 28174817 PTHLH rs7297051 C/T 0.24 0.86 (0.83–0.89) 1.48 10 14 0.23 0.89 (0.85–0.93) 2.89 10 7 3.12 10 20
12p11.2 28155080 PTHLH rs10771399 A/G 0.12 0.79 (0.78–0.87) 3.82 10 13 0.10 0.86 (0.80–0.91) 2.55 10 6 7.18 10 18
w16q12.1 52599188 TO 3 rs4784227 C/T 0.24 1.15 (1.11–1.19) 1.11 10 14 0.26 1.07 (1.02–1.12) 4.97 10 3 6.44 10 15
16q12.2 53813367 FTO rs17817449 T/G 0.41 0.91 (0.89–0.95) 2.83 10 7 0.41 0.95 (0.92–0.99) 0.02 5.26 10 8
16q12.2 53855291 FTO rs11075995 T/A 0.24 1.11 (1.07–1.15) 3.30 10 8 0.24 1.01 (0.97–1.06) 0.61 1.56 10 6
19p13.1 17389704 MERIT40 rs8170 G/A 0.19 1.15 (1.11–1.20) 1.35 10 12 0.19 1.17 (1.11–1.23) 7.29 10 10 6.64 10 21
w19p13.1 17393925 ADHB8 rs56069439 C/A 0.30 1.16 (1.13–1.20) 8.25 10 19 0.30 1.19 (1.14–1.24) 1.42 10 15 1.49 10 32
CI, conﬁdence interval; EAF, effect allele frequency; ER, oestrogen receptor; GWAS, genome-wide association studies; HR, hazard ratio; OR, odds ratio; SNP, single-nucleotide polymorphism.
*P values from iCOGS/BCAC and meta-analysis for ER-negative breast cancer were estimated by z-test. P values for BRCA1 carriers were estimated by a kinship-adjusted retrospective likelihood
approach.
wSNPs with more signiﬁcant associations with ER-negative disease than known index SNPs from these loci.
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eQTL SNP accounted for much of the inﬂuence of the rs4577254
SNP on ER-negative breast cancer risk (P¼ 9.07 10 4) and
vice versa (Supplementary Table 18). Thus, modulation of
TRMT61B expression may contribute in part to the risk of breast
cancer in this region. In the 13q22.1 locus, the strongest eQTLs in
the 735 TCGA breast tumours (BC765) involved PIBF1
(Supplementary Table 19). However, none of the SNPs strongly
associated with breast cancer risk in either of the two independent
13q22 loci showed associations with gene expression
(Supplementary Table 19, Supplementary Fig. 4). In contrast,
signiﬁcant associations with DIS3 expression were observed in the
BC241 and NB116 cohorts for many of the genome-wide sig-
niﬁcant SNPs in the locus represented by rs17181761 (NB116
eQTL P¼ 2.34 10 3) (Supplementary Table 19). While non-
signiﬁcant after accounting for multiple testing, these observa-
tions suggest that future studies should evaluate mechanistic
interactions between 13q22.1 SNPs and DIS3 expression. Eva-
luation of eQTLs in the 2q33 locus for the BC765 cohort found
that many of the 157 risk-associated SNPs (Table 2,
Supplementary Table 15) had strong associations with PPIL3
expression (rs188686860, P¼ 1.77 10 7; rs115635831,
P¼ 6.08 10 7; Supplementary Fig. 5) and little evidence of any
associations with other genes in the region (Supplementary
Table 20). This is one of the few known breast cancer risk loci
where the most signiﬁcant risk SNPs are strongly associated with
local gene expression. PPIL3 is located at the proximal end of the
locus, 270 kb upstream of CASP8, further suggesting that the 2q33
risk locus is independent of any inﬂuence on CASP8.
Functional characterization of the 2p23.2 locus. To identify
candidate SNPs and genes in the 2p23.2 locus driving ER-nega-
tive breast cancer risk, ENCODE chromatin biofeatures were
evaluated in primary human mammary epithelial cells (HMECs),
MCF7 ER-positive cells and MB-MDA-231 ER-negative cells30.
Sixteen of the 79 most signiﬁcantly associated SNPs
(Po3 10 7) in the region overlapped with three distinct
regulatory regions (Supplementary Figs 6 and 7). The most
signiﬁcantly associated ER-negative SNP, rs67073037 (Table 2)
was located in intron 1 of WDR43 near the transcription start site
in a region containing acetylated H3K27 and trimethylated H3K4
chromatin marks in normal HMECs and MB-MDA-231
ER-negative breast tumour cells, and a DNase hypersensitivity
cluster in ER-positive MCF7 cells (Supplementary Figs 6 and 7).
The three risk-associated SNPs (rs4407214, rs66604446 and
rs66768547) with the most signiﬁcant RegulomeDB scores (2b),
were located in the same chromatin marks in this region in
HMEC, MD-MBA-231 and MCF7 cells (http://regulomedb.org).
In addition, the top genotyped SNP (rs4577244) was located in a
monomethylated H3K4 mark adjacent to the core promoter
region of WDR43 in HMECs (Supplementary Fig. 6). Separately
rs11677283 and rs35617956 in introns 9 and 10 of WDR43 were
located in acetylated H3K27 and H3K9 chromatin marks in a
putative regulatory region in HMECs, but not in ER-negative
MD-MBA-231 cells.
Combining the eQTL results with these predictions, we tested
four genomic tiles spanning region 1 for enhancer activity in both
orientations using a luciferase reporter assay in the CAL51 ER-
negative breast cancer line and MCF10A normal mammary
epithelial cells (Fig. 3). The tile containing rs4407214 displayed
signiﬁcant enhancer activity (Po0.0001) in at least one orienta-
tion when compared with the negative control in MCF10A and
CAL51 (Fig. 3). In addition, the tile carrying the disease-
associated G allele showed signiﬁcantly (P¼ 0.0059) higher
activity than the T allele in MCF10A cells (Fig. 3). Similarly,
the disease-associated G-allele showed signiﬁcantly (P¼ 0.0059)
higher activity than the T-allele in a luciferase-based promoter
assay in MCF10A cells (P¼ 0.044) and CAL51 (P¼ 0.0078;
Supplementary Fig. 8). Consistent with these allele-speciﬁc
changes in transcriptional activity different protein complexes
in electrophoretic mobility shift assays were observed using
CAL51 and MCF10A nuclear extracts (Fig. 3). In addition, Pol2
ChIA-PET in MCF7 breast cancer cells revealed an interaction
between Region 1 and the promoter of TRMT61B (Fig. 3), which
had the strongest eQTL signal in the locus. These results are
consistent with modiﬁcation of Pol2 binding to this region by
rs4407214 in lymphoblastoid cells31 and suggest the presence of a
transcriptional enhancer in the region. Separately, the ChIA-PET
data further suggest that Region 2 in WDR43 may interact with
the promoter of WDR43 (Fig. 3). Thus, WDR43 and TRMT61B
may be regulated by interactions of enhancers inWDR43 with the
core WDR43 and TRMT61B promoters and may jointly inﬂuence
breast cancer risk in this region.
Functional characterization of the 13q22 locus. The SNPs most
signiﬁcantly associated with ER-negative breast cancer in the two
13q22 loci formed two small clusters in a 4-kb region around
rs17181761 and a 10-kb region around rs8002929. Bioinformatics
analysis and chromatin feature analysis identiﬁed weak DNaseI
Table 2 | Novel associations of common genetic variants with ER-negative breast cancer risk.
iCOGS/GWAS ER-negative BRCA1 carriers Meta-analysis
Location Position Nearest gene SNP r2 Allele EAF OR (95% CI) P* EAF HR (95% CI) P* P*
2p23.2 29119585 WDR43 rs67073037 0.98 A/T 0.24 0.92 (0.88–0.95) 3.20 106 0.20 0.92 (0.87–0.96) 4.58 104 4.76 109
2p23.2 29160421 WDR43 rs6734079 0.99 T/A 0.23 0.92 (0.88–0.95) 3.99 10 6 0.20 0.92 (0.87–0.96) 4.55 104 5.50 109
2p23.2 29120733 WDR43 rs4577244 1 C/T 0.23 0.92 (0.89–0.95) 6.36 10 6 0.20 0.92 (0.88–0.96) 5.48 104 1.05 108
2q33 201717014 CLK1 rs74943274 0.98 G/A 0.015 1.34 (1.18–1.52) 5.89 106 0.02 1.20 (1.03–1.41) 0.012 6.00 10 7
2q33 201733341 CLK1/PPIL3 rs188686860 0.98 C/T 0.016 1.36 (1.20–1.53) 1.16 106 0.02 1.22 (1.04–1.42) 0.012 8.34 108
2q33 201743594 PPIL3 rs115635831 1 G/A 0.015 1.36 (1.20–1.54) 1.07 10 6 0.02 1.21 (1.03–1.41) 0.018 1.26 10 7
2q33 201935871 FAM126B/
NDUFB3
rs114962751 1 T/A 0.016 1.36 (1.20–1.53) 1.17 106 0.02 1.22 (1.05–1.42) 0.011 7.24 108
13q22 73957681 KLF5/KLF12 rs6562760 1 G/A 0.23 0.92 (0.89–0.96) 1.85 10 5 0.20 0.89 (0.85–0.94) 2.85 106 4.98 10 10
13q22 73960952 KLF5/KLF12 rs2181965 0.99 G/A 0.23 0.92 (0.89–0.96) 2.16 10 5 0.20 0.89 (0.85–0.94) 2.39 10 6 5.04 10 10
13q22 73964519 KLF5/KLF12 rs8002929 1 A/G 0.23 0.93 (0.89–0.96) 2.52 10 5 0.20 0.89 (0.85–0.94) 1.71 106 5.35 10 10
13q22 73806982 KLF5/KLF12 rs12870942 0.99 T/C 0.32 1.09 (1.05–1.13) 2.71 10 7 0.30 1.06 (1.01–1.10) 0.01 3.75 10 8
13q22 73811471 KLF5/KLF12 rs17181761 0.99 A/C 0.32 1.09 (1.05–1.12) 3.44 10 7 0.30 1.06 (1.01–1.10) 9.29 10 3 4.23 108
13q22 73813803 KLF5/KLF12 rs9573140 1 A/G 0.32 1.09 (1.05–1.12) 3.77 10 7 0.30 1.06 (1.01–1.10) 0.01 5.38 10 8
CI, conﬁdence interval; EAF, Effect allele frequency; ER, oestrogen receptor; GWAS, genome-wide association studies; HR, hazard ratio; OR, odds ratio; r2, imputation accuracy; SNP, single-nucleotide
polymorphism.
*P values from iCOGS/BCAC and meta-analysis for ER-negative breast cancer were estimated by z-test. P values for BRCA1 carriers were estimated by a kinship-adjusted retrospective likelihood
approach.
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hypersensitivity sites, CTCF binding and monomethylated H3K4
sites in both regions in HMEC cells, consistent with weak enhancer
activity (Supplementary Figs 9 and 10). Both rs17181761 and
rs12870942 in the proximal locus are associated with transcriptional
activity in HMECs, whereas rs8002929 and rs927683 in the distal
locus are associated with enhancer and DNAse hypersensitivity sites
in HMECs, respectively (http://regulomedb.org). Both 13q22 loci are
located in a non-genic 600-kb region between the KLF5 and KLF12
kruppel-like transcription factor genes. This segment of chromo-
some 13 is frequently deleted in a spectrum of cancers32,33. GWAS
have also identiﬁed a pancreatic cancer risk locus in the region
between KLF5 and KLF12 (refs 34–36). However, the rs9543325
SNP from the pancreatic cancer studies was only marginally
associated with ER-negative breast cancer risk (P¼ 0.03) in the
meta-analysis suggesting that the signals are independent.
Functional characterization of the 2q33 locus. The SNPs most
signiﬁcantly associated with ER-negative breast cancer in the 2q33
locus range across a 350-kb region that contains nine genes
(Supplementary Fig. 6). This region contains at least 10 strong
enhancer regions in HMECs and 12 strong enhancer regions in MD-
MBA-231 cells associated with acetylated H3K27 and trimethylated
H3K4 chromatin marks. As noted above, many of the 157 SNPs
most signiﬁcantly associated with ER-negative breast cancer are
associated with PPIL3 expression. Seven of these also scored as
functional candidates by RegulomeDB (score¼ 3a; rs17467658,
rs17383256, rs17467916, rs114567273, rs76377168, rs116509920 and
rs116724456). Of these rs17467658 in CLK1 and rs17383256 in
the ORC2 gene are located in DNAse hypersensitivity sites and
strong enhancer regions in HMEC and MD-MBA-231 cells
(http://www.roadmapepigenomics.org; Supplementary Figs 11 and
12). In addition, rs116509920 and rs116724456 are associated with
PPIL3 expression (P¼ 5.85 10 7), although neither SNP is asso-
ciated with an enhancer or suppressor region. The genotyped SNP
most signiﬁcantly associated with risk, rs114962751, is located in
acetylated H3K27 and trimethylated H3K4 chromatin marks in a
bidirectional promoter for FAM126B and NDUFB3 in HMEC and
MD-MBA-231 cells (Supplementary Figs 11 and 12). Similarly, the
rs74943274 genotyped risk SNP (Table 2) is located near the
30-untranslated region of CLK1 and is associated with PPIL3
expression (P¼ 2.37 10 6). However, rs78258606 is perhaps a
more likely candidate driver of ER-negative risk in this locus
because the SNP is associated with ER-negative breast cancer
(P¼ 1.9 10 7), is located in the CLK1 promoter in acetylated
H3K27 and trimethylated H3K4 chromatin marks in HMEC and
MD-MBA-231 cells and DNase hypersensitivity sites in MCF7 cells,
and is associated with PPIL3 expression (P¼ 2.71 10 7)
(Supplementary Figs 11 and 12). Further ﬁne mapping and func-
tional characterization of this locus is needed to resolve the under-
lying functional effects and identify the genes inﬂuencing ER-negative
breast cancer risk.
Discussion
When including the four 2p23.2, 13q22 and 2q33 novel loci
identiﬁed in this meta-analysis, 23 independent loci have shown
genome-wide signiﬁcant associations with ER-negative disease,
including 10 loci showing no associations or only weak
associations with ER-positive disease. In total, 63 loci have
shown at least marginal signiﬁcance (Po0.05) with ER-negative
breast cancer. In BRCA1 mutation carriers, 27 independent loci
(Po0.05) have been associated with modiﬁed breast cancer
risk27. The percentage of the familial risk for ER-negative disease
explained by SNPs is not well deﬁned because there is currently
no good estimate for the familial relative risk for ER-negative
disease. However, assuming that the estimate is similar to that for
overall breast cancer (twofold for a ﬁrst-degree relative), and
based on the estimated frequencies and ORs from the iCOGS
data, the SNPs in the known breast cancer risk loci explain 9.8%
of the familial risk and the SNPs in the four new loci account for a
further 0.8%. The addition of these new ER-negative loci may
improve overall risk prediction models for ER-negative disease in
the general population and for breast cancer among BRCA1
mutation carriers by enhancing the contribution of current
polygenic risk prediction models21,22. Furthermore, ﬁne mapping
and functional studies of these loci may provide further insight
into the aetiology of ER-negative breast cancer.
Methods
Study populations. Details of the subjects, genotyping and quality control mea-
sures for the BCAC GWAS and iCOGS data3, BPC3 (ref. 16), EBCG37,
TNBCC14,38 and BRCA1 (ref. 22) are described elsewhere. Analyses were restricted
to women of European ancestry. Overall, 42 BCAC studies provided the iCOGS
genotyping data for ER-negative breast cancer cases and controls. In addition, 11
breast cancer studies provided GWAS genotyping data. Forty ﬁve CIMBA studies
provided iCOGS genotyping on 15,252 BRCA1 mutation carriers, of whom 7,797
were affected with breast cancer.
Genotype data. Genotyping and imputation details for each study are shown in
Supplementary Table 1.
Imputation. We performed imputation separately for BRCA1 carriers, 11 GWAS,
BCAC-iCOGS and TNBCC-iCOGS samples. We imputed variants from the 1000
Genomes Project data using the v3 April 2012 release39 as the reference panel.
Imputation was based on the 1000 Genomes Project data with singletons removed.
Eight BCAC GWAS were imputed in a two-step procedure, with prephasing using
the SHAPEIT software and imputation of the phased data in the second with
IMPUTEv2 (ref. 40). For the remaining three GWAS (BPC3, TNBCC and EBCG),
imputation was performed using MACH (version 1.0.18) and Minimac (version
2012.8.15)41. The iCOGS data were also imputed with two-stage procedure
involving SHAPEIT and IMPUTEv2. To perform the imputation we divided the
data into segments of B5Mb each. The iCOGS samples were divided into 10
subsets, keeping all subjects from individual studies in the same set. Estimates and
s.e.’s were obtained using logistic regression adjusting for study and 9 principal
components. GWAS SNPs were excluded if the imputation accuracy was r2o0.3 or
if the minor allele frequency (MAF) waso0.01, TNBCC SNPs were excluded when
the imputation accuracy was r2o0.9 and MAFo0.05, iCOGS SNPs were excluded
when r2o¼ 0.3 and MAFo0.005. Regions with evidence of genome-wide
signiﬁcant associations (Po5 10 8) were reimputed in iCOGS, using
IMPUTEv2 but without prephasing in SHAPEIT to improve imputation accuracy.
In addition, the number of MCMC iterations were increased from 30 to 90, and the
buffer region was increased to ±500 kb from any signiﬁcantly associated SNP in
the region.
Meta-analysis. A ﬁxed effects meta-analysis of ER-negative breast cancer asso-
ciations was conducted using an inverse variance approach assuming ﬁxed effects,
as implemented in METAL42. The effect estimates used were the logarithm of the
per-allele HR estimate for the association with breast cancer risk in BRCA1 and
BRCA2 mutation carriers and the logarithm of the per-allele OR estimate for the
association with breast cancer status in GWAS and iCOGS analyses, both of which
were assumed to approximate the same relative risk. For the associations in BRCA1
mutation carriers, a kinship-adjusted variance estimator was used12. P-values were
estimated by z-test.
Heterogeneity analysis. Heterogeneity across estimates from BCAC and iCOGS
were evaluated using a Cochran Q test and I2 for the proportion of total variability
explained by heterogeneity in the effect sizes43. Associations with ER-positive and
ER-negative subgroups of BRCA1 carriers were evaluated using an extension of the
retrospective likelihood approach to model the simultaneous effect of each SNP on
more than one tumour subtype27. The consistency between breast cancer
associations for breast cancer susceptibility variants in the general population and
associations in BRCA1 and BRCA2 carriers were evaluated using the intraclass
correlation (ICC)27. The ICC was estimated based on a one-way random-effects
model and tested for agreement in absolute values of log HR.
Locus coverage. Locus boundaries were deﬁned so that all SNPs with r2Z0.1 with
the most signiﬁcantly associated SNP were included. SNPs with MAFo0.005 were
excluded. Linkage disequilibrium blocks were deﬁned at r2Z0.8. Each linkage
disequilibrium block was evaluated for the presence of at least one genotyped or
imputed SNP. If imputed, then the imputation accuracy was considered.
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Expression quantitative trait locus analysis. eQTL analysis was performed for
all protein coding genes within 1Mb, up- and downstream of the SNP most
signiﬁcantly associated with ER-negative breast cancer risk in each locus. Normal
breast (NB116; n¼ 116) and breast cancer (BC241, n¼ 241) are comprised of
women of Norwegian descent. Gene expression data for the majority of women in
NB116 were derived from normal breast tissue in women who had not been
affected with breast cancer; data for ten women were derived from normal tissue
adjacent to a tumour. Gene expression data for BC241 were derived from breast
tumours (70 ER-negative and 170 ER-positive). Genotyping was performed with
the iCOGS SNP array, and gene expression levels were measured with the Agilent
44K array44,45. BC765 (n¼ 765) is the TCGA breast cancer cohort composed
of 139 ER-negative, 571 ER-positive and 55 undeﬁned breast tumours; all
non-European samples (as determined by clustering and PCA) were excluded
from this analysis46. Germline genotype data from Affymetrix SNP 6 array were
obtained from TCGA dbGAP data portal46. Gene expression levels for the breast
tumours were assayed by RNA sequencing, RSEM (RNaseq by Expectation-
Maximization21) normalized per gene, as obtained from the TCGA consortium
portal46. The data were log2 transformed, and unexpressed genes were excluded
prior to eQTL analysis. There is no overlap between women recruited to each of
these studies. The genotyping data were processed as follows: SNPs with call rates
o0.95 or minor allele frequencies o0.05 or Hardy–Weinberg equilibrium
(Po10 13) were excluded. Samples with call rates below 80% were excluded.
Identity by state was computed with the R GenABEL package47 and closely related
samples with IBS40.95 were removed. Imputation was performed on the iCOGS
and Affymetrix6 germline genotype data using the 1000 Genomes Project March
2012 v.3 release as the reference data set. A two-stage imputation procedure was
used as described above. The inﬂuence of SNPs on gene expression was assessed
using a linear regression model. An additive effect was assumed by modelling copy
number of the rare allele, that is, 0, 1 or 2, for a given genotype.
Candidate gene analysis. TCGA has performed extensive genomic analysis of
tumours from a large number of tissue types including over 1,000 breast tumours.
All genes in the novel loci were evaluated for coding somatic sequence variants in
TCGA. Breast tumours with log2 copy-number data in the TCGA data were
analysed for deletion and ampliﬁcation of each candidate gene using the cBio
portal48,49.
Informatics and chromatin biofeatures. Candidate SNPs were evaluated using
SNPInfo (http://snpinfo.niehs.nih.gov) and SNPnexus (http://snp-nexus.org/test/
snpnexus). The presence of SNPs in transcription factor binding sites using
TRANSFAC and miRNA binding sites using TargetScan were noted. Regulatory
potential scores (ESPERR Regulatory Potential) were obtained from the UCSC
genome bioinformatics browser (http://genome.ucsc.edu/). RegulomeDB (http://
regulomedb.org) was used to assess SNPs for transcription factor recognition
motifs, open chromatin structure based on FAIRE and DNAse-seq analysis and
protein binding sites based on ChIP-seq data. Chromatin biofeatures in HMEC and
MCF7 cells were assessed using ENCODE layers on the UCSC browser (http://
genome.ucsc.edu/). Enhancers active in the mammary cell types MCF7 and HMEC
were cross-referenced with candidate SNPs.
Luciferase reporter assays. Genomic tiles spanning regions containing SNPs
with indication of regulatory activity by RegulomeDB were generated. Regions
containing the major and minor alleles within the 2p23.2 region spanning 2,229 bp
(chr2:29,117,333-29,119,561) were generated by PCR using BAC DNA CTD-
3216P10 as template. Forward and reverse primers contained attB1 and attB2
sequences, respectively, to aid in recombinational cloning. Tiles were cloned in
both a forward and reverse orientation upstream of the SV40 promoter by
recombination in the ﬁreﬂy luciferase reporter vector pGL3-Pro-attb vector
designed to test for enhancer regions. This vector is a modiﬁcation of pGL3-
Promoter (Invitrogen) adding attB sites surrounding the ccdb gene. The clone
containing the tile was co-transfected in eight replicates using LipoFectamine 2000
(Life Technologies) into MCF10A or CAL51 cells with pRL-CMV (Promega), an
internal control expressing Renilla luciferase, per well of 96-well plates. Luciferase
activity was measured 24-h post transfection by Dual Glo Luciferase Assay (Pro-
mega). Transfections were repeated in two independent experiments with similar
results. The inﬂuence of the common and rare alleles of rs4407214 on promoter
activity in the pGL3-Promoter vector (Invitrogen) were assessed using the same
methodology. Primers are available on request.
Electromobility shift assays. Nuclear proteins from MCF10A and CAL51 cells
were extracted using a hypotonic lysis buffer (10mM HEPES, pH 7.9, 1.5mM
MgCl2, 10mM KCL) supplemented with DTT and protease inhibitors, followed by
an extraction buffer (20mM HEPES, ph 7.9, 1.5mM MgCl2, 0.42M NaCl, 0.2mM
EDTA, 25% v/v glycerol) supplemented with DTT and protease inhibitors. Elec-
trophoretic mobility shift assays probes were designed to cover each SNP±20 base
pairs, for both major and minor alleles. Probe pairs were dissolved in water and
annealed at a concentration of 10 mM each. Probes were labelled with ATP (g-32 P;
Perkin Elmer) using T4 polynucleotide kinase and cleaned using the QiaQuick
Nucleotide Removal Kit (Qiagen). Labelled and unlabelled probes were then
incubated with protein extracts using LightShift Poly(dI–dC) (Thermo) and a
binding buffer (10mM Tris, 50mM KCl, 1mM DTT, pH 7.4) and electrophoresed
on a 6% acrylamide gel overnight at 83 V. Gels were dried and ﬁlms were exposed
for 4–24 h. Probe sequences are shown in Supplementary Table 21.
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